RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx is well positioned because its FDA-cleared RenovoCath is gaining commercial traction, with active cancer centers rising from about 5 in September 2025 to 26 currently and a path to 36 by the end of 2026, supporting revenue growth that reached $1.1 million in fiscal Q3 2026, up 301% year over year. Its core TAMP platform and lead candidate RenovoGem address a large unmet need in locally advanced pancreatic cancer by targeting tumors directly and potentially reducing toxicity versus systemic therapy, while the DMC’s recommendation to continue the Phase III TIGeR-PaC trial adds credibility to the program. With $10 million in cash, no debt, and a roughly billion-dollar market opportunity, the company has meaningful financial flexibility and multiple catalysts tied to commercialization and 2027 trial milestones.

RenovoRx is exposed to substantial fundamental risk because its value depends on a clinical-stage platform that has not yet proven safety, efficacy, or regulatory success, leaving the company vulnerable to trial setbacks and approval delays. Its commercialization prospects remain uncertain, and even if development advances, the business still faces reimbursement risk, intense competition, and the possibility that healthcare priorities or investor appetite for biotech weaken. In addition, balance sheet and liquidity concerns could pressure execution, making the stock especially dependent on favorable outcomes across multiple highly uncertain milestones.